Alison is an Advanced Nuclear Medicine Technologist with more than 25 years of experience spanning clinical practice, leadership, and research. She holds a Master of Molecular Imaging Technology from The University of Queensland and has advanced expertise in PET/CT, PET/MR, SPECT/CT, BMD, Theranostics, and radiopharmacy.
She is currently based at the Herston Imaging Research Facility and the Royal Brisbane and Women’s Hospital, where she leads the Nuclear Medicine and Bone Mineral Density portfolios, coordinates national multi-centre imaging studies, and contributes to the development and optimisation of PET/CT and PET/MR research protocols.
Alison has a strong record of translating emerging molecular imaging technologies into clinical practice, mentoring junior staff and trainees, and contributing to professional education and governance. Her academic and clinical interests focus on evidence-based imaging, research translation, and advancing patient-centred nuclear medicine care.
The Australian Epilepsy Project has seven MRI scanning sites across five states as part of a national network to provide epilepsy patients with access to advanced diagnostic testing that was otherwise
15 October 2025
Neurodesk’s innovative ability to help researchers process and analyse massive neuroimaging datasets was recognised late last month at the 2025 National iAwards, presented in Adelaide. Neurodesk is
07 October 2025
Reported by 9News, Clinical Director of The Florey Professor Graeme Jackson was interviewed about the technology developed at the Australian Epilepsy project.
26 June 2025
Donanemab, developed by Lilly, is the first disease-modifying treatment for early-stage Alzheimer’s disease to be approved for use in Australia. The National Imaging Facility supported its developme
16 June 2025